Takeda Unit Fights Accord's Bid To Nix Crohn's Drug IP
A unit of pharma giant Takeda has hit back at Accord's bid to invalidate two patents covering treatment regimens for Crohn's disease, arguing that the generic-drug maker is seeking to clear...To view the full article, register now.
Already a subscriber? Click here to view full article